Advertisement
Advertisement

TheBody.com/TheBodyPRO.com covers The 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)

Renal Impairment in the D:A:D Study

May/June 2012

An analysis from the large prospective D:A:D cohort looked at patients with normal renal function at baseline and associations between renal changes and individual HIV drugs and changes in treatment, adjusting for renal and HIV related risk factors.

This included >22,600 patients who started ART from 2004 with eGFR >90 mL/min. Progression of renal dysfunction was defined as eGFR decline to <70 (the threshold for proactive switches away from individual ARVs with a concern for renal toxicity), confirmed eGFR <60 mL/min.

During a median follow-up of 4.5 years (IQR 2.7-6.1), approximately 2.1% patients (n=468) progressed to confirmed eGFR <70 and 0.6% (n=131) to chronic kidney disease (CKD) with incidence rates (IR; 95%CI per 1000 PY) of 4.78 (4.35 to 5.22) and 1.33 (1.10 to 1.56), respectively.

In people with reduced eGFR, tenofovir was the only ARV that was actively switched (at eGFR 60-70 vs. >90) with an adjusted IR ratio 1.72 (95%CI 1.38 to 2.14). This was interpreted as being due to the general awareness of tenofovir and renal complications.

Cumulative use of tenofovir and atazanavir/ritonavir were independently associated with increased rates of confirmed eGFR ≤70, but not CKD. Lopinavir/ritonavir (Kaletra) was also associated with both increased risk for renal endpoints and abacavir was associated only with higher rates of CKD. See Table 1.


Table 1: Cumulative Exposure (IRR per Year) to ART and Renal Endpoints in D:A:D
ARVConfirmed eGFR <70

IRR (95%CI)

P-ValueCKD

IRR (95%CI)

P-Value
tenofovir 1.18 (1/12-1.25) <0.0001 1.08 (0.971.21) 0.16
abacavir 1.04 (0.99-1.09) 0.061 1.08 (1.00-1.17) 0.046
atazanavir/r 1.20 (1.09-1.32) 0.0002 1.16 (0.95-1.42) 0.15
atazanavir 1.10 (0.92-1.33) 0.29 0.80 (0.45-1.43) 0.45
lopinavir/r 1.11 (1.05-1.17) 0.0002 1.24 (1.13-1.36) <0.0001
other PI/r 1.03 (0.95-1.11) 0.52 1.11 (0.97-1.26) 0.13


The relationships to use of tenofovir, atazanavir/r and lopinavir/r were with current use, whereas >1 year after drug discontinuation the rates approached 1.0. Other predictors (adjusted IRR; 95%CI) of confirmed eGFR ≤70 were age (2.63 per 10 years: 2.33 to 2.96), diabetes (1.54; 1.06 to 2.23), hepatitis B virus (1.56; 1.10 to 2.22), hepatitis C virus (1.47; 1.09 to 2.00), current CD4 count (0.75 per doubling; 0.69 to 0.82) and prior AIDS (1.38; 1.13 to 1.69).


Advertisement

Comment

Although the study concluded that these rates were generally low, it also highlighted that compared to lifetime use of ART, follow-up may be too short to pick up such dramatic declines in renal function, especially if rates continue or increase with age. Nevertheless, over five years, incidence of progression of eGFR from >90 to <70 were twice as high in patients who used tenofovir (vs never used).

The study suggested that proactive switching from tenofovir was protective after one year and that closer monitoring of renal function may be appropriate for people using atazanavir/r or lopinavir/r.

See also the recent publication in AIDS of the VA cohort analysis of tenofovir and renal function, reported later in this issue of HTB.


Reference

Ryom L et al for the D:A:D Study Group. Exposure to ARV and the risk of renal impairment among HIV+ persons with normal baseline renal function: the D:A:D study. 19th CROI, 5-8 March 2012, Seattle. Poster abstract 865.

Links to external websites are current at time of posting but not maintained.




This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement